Project Details
Description
Phase 2 Trial of Neoadjuvant KRAS G12C directed therapy with Adagrasib (MRTX849) with or without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)
| Status | Finished |
|---|---|
| Effective start/end date | 2/1/24 → 6/30/25 |
Funding
- JOHNS HOPKINS UNIVERSITY
- MIRATI THERAPEUTICS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.